Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Gilead Sciences Inc (NASDAQ:GILD): A Balanced Dividend Play with Strong Financial Health and Profitability - ChartMill

AI-generated analysis

πŸ” Gilead Sciences Inc (NASDAQ:GILD) was identified as a top pick using the ChartMill "Best Dividend Stocks" screener.

πŸ’° The company achieved a Dividend Rating of 7 out of 10, offering a current yield of 2.45%.

πŸ“Š This yield significantly outperforms the S&P 500 average of 1.81% and the biotechnology industry average of 0.71%.

βœ… GILD's dividend is sustainable with a payout ratio of 47.04%, paying out less than half of net income.

πŸ“… The company has increased its dividend for at least 10 consecutive years, showing a reliable track record.

πŸ’Ό Profitability is strong with a ChartMill Profitability Rating of 8 out of 10 and operating margins exceeding 97% of peers.

πŸš€ Gilead boasts high returns including a Return on Equity (ROE) of 37.49% and ROIC of 19.49%.

πŸ›οΈ Financial health is solid with an Altman-Z score of 4.36 indicating very low bankruptcy risk.

πŸ’Έ The debt-to-free-cash-flow ratio of 2.64 means the company could pay off all debt in under three years.

πŸ“‰ Liquidity metrics like current ratio (1.55) are lower than peers but still indicate a healthy ability to cover obligations.

πŸ… GILD is reasonably valued with a Price/Earnings (P/E) ratio of 16.00 compared to the S&P 500 average of 27.42.

πŸ“ˆ Future earnings growth is expected to accelerate to over 10% per year in the coming years.

πŸ’Š Gilead focuses on developing therapies for HIV, viral hepatitis, COVID-19, and oncology.

πŸ”„ The company is actively buying back shares, further benefiting remaining shareholders.

βš–οΈ While immediate liquidity and past growth are not class-leading, strong solvency makes it a stable investment.

πŸ“‰ The stock offers a compelling mix of attributes rare in the biotechnology sector.

Bullish Signals
  • Gilead Sciences earned a ChartMill Dividend Rating of 7 out of 10, offering a current dividend yield of 2.45% which significantly outperforms the S&P 500 average of 1.81% and the Biotechnology industry average of 0.71%.
  • The company maintains a healthy payout ratio of 47.04%, paying out less than half of its net income as dividends, while boasting a track record of increasing its dividend for at least 10 consecutive years.
  • Gilead achieved an impressive ChartMill Profitability Rating of 8 out of 10, with an operating margin of 39.98% that outperforms 97.67% of its biotechnology peers.
  • The company demonstrates elite returns with a Return on Equity (ROE) of 37.49% and a Return on Invested Capital (ROIC) of 19.49%, reinforcing the stability of its dividend coverage.
  • Gilead's strong solvency is evidenced by an Altman-Z score of 4.36 indicating low bankruptcy risk, and a debt-to-free-cash-flow ratio of 2.64 suggesting it could pay off all debt in under three years.
  • The company is actively buying back shares, which directly benefits remaining shareholders, while also generating strong free cash flow to support these activities.
  • Gilead trades at a significant valuation discount with a P/E ratio of 16.00 compared to the S&P 500 average of 27.42 and the biotechnology industry average of 48.47.
  • Analysts expect an acceleration in Earnings Per Share (EPS) growth of over 10% per year in the coming years, creating a compelling risk/reward profile for investors.
Risk Factors
  • GILD's current ratio of 1.55 and quick ratio of 1.40 are lower than many of its industry peers, indicating weaker immediate liquidity compared to competitors despite still covering short-term obligations.
  • The company has experienced low single digits in past and future earnings growth, which is not considered spectacular for a growth-oriented analysis.
  • GILD generates moderate dividend growth of only 3.30% annually, limiting potential yield enhancement for long-term income investors.
  • The stock trades at a forward P/E of 14.75, reflecting that the market does not currently price in explosive growth or significant upside beyond steady performance.
Full Analysis
Gilead Sciences Inc (NASDAQ:GILD) has been identified as a strong candidate within the "Best Dividend Stocks" screener due to its robust financial health, profitability, and established dividend track record. The company earns a ChartMill Dividend Rating of 7 out of 10 based on a current yield of 2.45%, which significantly exceeds both the broader S&P 500 average of 1.81% and the biotechnology industry average of 0.71%. The dividend's sustainability is reinforced by a healthy payout ratio of approximately 47% and a consistent history of annual increases spanning at least 10 years, with an annual growth rate around 3.30%. Financial strength further supports GILD's status as a reliable income stock, highlighted by an elite Profitability Rating of 8 out of 10 driven by exceptional margins that outperform the vast majority of biotechnology peers. The firm generates strong returns on capital, evidenced by a Return on Equity of 37.49% and a Return on Invested Capital of 19.49%, ensuring ample cash flow to cover dividend obligations even during potential market downturns. Additionally, GILD demonstrates solid solvency with an Altman-Z score indicating low bankruptcy risk and a debt-to-free-cash-flow ratio of 2.64, suggesting the company could repay its total debt in under three years using current free cash flow generation. Valuation metrics also present an attractive entry point for income-focused investors, with a Price/Earnings ratio of 16.00 that trades at a significant discount to both the S&P 500 average of 27.42 and the biotechnology sector average of 48.47. This reasonable valuation aligns with expectations of moderate current earnings growth in low single digits, although analysts project an acceleration in earnings per share growth exceeding 10% annually in the coming years. While GILD's liquidity ratios are slightly lower than peers due to a highly competitive industry landscape rather than financial distress, the strong solvency and cash flow position make it a stable proposition for long-term investing strategies.